Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Advancing in the CHallenge of Improving Lymphoma and LEukemia Survival

Project description

Training in blood cancer research

Leukaemia and lymphoma are two of the most difficult cancers to treat, demanding new therapies that go beyond existing approaches. Supported by the Marie Skłodowska-Curie Actions programme, the ACHILLES project will train doctoral candidates in experimental haemato-oncology. Its focus is on developing new models and creating targeted therapies. Cutting-edge tools such as AI, multi-omics, and computational modelling will be used to design better diagnostics and improve treatment responses. With a strong patient-centred vision, ACHILLES aims to bridge science and clinical practice, advancing Europe’s Beating Cancer Plan and improving outcomes for patients worldwide.

Objective

ACHILLES is a Doctoral Network (DN) program designed to train the next generation of leaders in hemato-oncology, with a focus on the development of novel therapeutic solutions for hematological malignancies. The network brings together 14 institutions from 10 EU countries and one associated state, along with partners from the biotechnology and drug discovery sectors, including two European policy leaders in hematology, the European Hematology Association (EHA) and the European School of Hematology (ESH). Through this collaboration, ACHILLES will train 16 Doctoral Candidates (DCs) to develop essential skills in experimental hemato-oncology, including the design, development, and preclinical validation of innovative therapies.
ACHILLES is structured around three key scientific objectives (SOs): (1) creating novel experimental models and analytical methods, (2) exploring the oncogenic mechanisms of hematologic malignancies, and (3) developing and validating new therapies, especially targeted treatments for leukemia and lymphoma. The program will integrate cutting-edge technologies such as AI, multi-omics, and computational modeling to push the boundaries of current research and therapy development. These innovations will be applied to generate better diagnostic tools, predict treatment responses, and optimize therapeutic strategies.
With a patient-centered approach, ACHILLES aims to foster both academic and industrial collaboration, bridging gaps between scientific research and clinical application. This initiative aligns with the EU's Beating Cancer Plan, with a particular focus on improving survival rates and treatment accessibility, especially in Widening Countries. Through strong academic-industrial partnerships, ACHILLES will help create a sustainable impact on the field of hemato-oncology, advancing research, therapies, and ultimately the health outcomes of leukemia and lymphoma patients worldwide.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral Networks

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2024-DN-01

See all projects funded under this call

Coordinator

FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS
Net EU contribution
€ 564 376,32
Address
CARRETERA DE CAN RUTI CAMI DE LES ESCOLES S/N
08916 Badalona
Spain
Region
Este Cataluña Barcelona
Activity type
Research Organisations
Links
Total cost
No data

Participants (13)

Partners (19)